Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loss of SARM1 Improves Phenotypes in a Mouse Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

Neurology. Genetics·2026
Same author

An unusual granulomatous tinea due to <i>Nannizzia incurvata</i> in Germany without evidence of an acquisition from outside Europe and reduced itraconazole susceptibility.

Medical mycology case reports·2026
Same author

The dorsal aortic compartment is a developmental source of brown adipose tissue in mice.

Nature communications·2026
Same author

Bullous lichen sclerosus: A rare differential diagnosis of a blistering genital dermatosis.

JAAD case reports·2025
Same author

SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy.

The Journal of clinical investigation·2025
Same author

Does DNA extraction affect the specificity of a PCR method claiming the specific detectability of a genome-edited plant?

GM crops & food·2024

Related Experiment Video

Updated: May 13, 2026

SorLA and CLC:CLF-1-dependent Downregulation of CNTFR&#945; as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
10:16

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

Foam cell specific LXRα ligand.

Radmila Feldmann1, Anne Geikowski, Christopher Weidner

  • 1Otto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany.

Plos One
|March 2, 2013
PubMed
Summary
This summary is machine-generated.

A novel compound, STX4, effectively targets liver X receptor alpha (LXRα) to reduce cholesterol in foam cells, offering a promising therapeutic lead for atherosclerosis without increasing triglycerides.

More Related Videos

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

Related Experiment Videos

Last Updated: May 13, 2026

SorLA and CLC:CLF-1-dependent Downregulation of CNTFR&#945; as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
10:16

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Liver X receptor alpha (LXRα) is a key regulator of cholesterol metabolism.
  • LXRα plays a crucial role in reverse cholesterol transport in macrophages.
  • Dysregulation of LXRα is implicated in the development of atherosclerosis.

Purpose of the Study:

  • To optimize a novel stilbenoid structure (STX4) as a selective LXRα ligand.
  • To evaluate the athero-protective effects of STX4 in cellular models.
  • To investigate STX4 as a potential therapeutic agent for atherosclerosis.

Main Methods:

  • Optimization of STX4 for nanomolar efficacy in LXRα reporter-gene assays.
  • Gene expression analyses in THP1-derived macrophages and oxLDL-loaded foam cells.
  • Assessment of cellular cholesterol and triglyceride levels following STX4 treatment.

Main Results:

  • STX4 selectively activated LXRα over LXRβ with nanomolar potency.
  • STX4 demonstrated athero-protective effects in foam cells, comparable to the synthetic ligand T09.
  • STX4 significantly reduced cellular cholesterol without increasing triglyceride levels, unlike T09.
  • Combinatorial treatment with STX4 and T09 showed additive effects on LXRα activation and gene expression.

Conclusions:

  • STX4 is a novel LXRα ligand with potential for studying anti-atherogenic processes.
  • STX4 represents a promising lead structure for pharmaceutical development in atherosclerosis treatment.